Cargando…
The impact of pharmacist early active consultation (PEAC) on multidrug resistance organism treatment outcomes: A prospective historically controlled study
Background and aim: Infectious disease (ID) consultation can improve multidrug-resistant organism (MDRO) treatment outcomes. However, the impact of clinical pharmacists’ ID consultation on MDRO therapy, especially early initiation, has not been reported. In this study, we try to explore the impact o...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017476/ https://www.ncbi.nlm.nih.gov/pubmed/36937879 http://dx.doi.org/10.3389/fphar.2023.1128219 |
_version_ | 1784907593952526336 |
---|---|
author | Du, Qian Xi, Xin Dong, Jie Zhang, Tongyan Li, Dongxuan Dong, Yuzhu Li, Wenjun Huang, Guili Zhu, Jun Ran, Hailong Gou, Jinghui Chen, Cheng Bai, Zhanfeng Liu, Qinglong Yao, Wei Zhang, Lei Bi, Yutian Liu, Songqing |
author_facet | Du, Qian Xi, Xin Dong, Jie Zhang, Tongyan Li, Dongxuan Dong, Yuzhu Li, Wenjun Huang, Guili Zhu, Jun Ran, Hailong Gou, Jinghui Chen, Cheng Bai, Zhanfeng Liu, Qinglong Yao, Wei Zhang, Lei Bi, Yutian Liu, Songqing |
author_sort | Du, Qian |
collection | PubMed |
description | Background and aim: Infectious disease (ID) consultation can improve multidrug-resistant organism (MDRO) treatment outcomes. However, the impact of clinical pharmacists’ ID consultation on MDRO therapy, especially early initiation, has not been reported. In this study, we try to explore the impact of the pharmacist early active consultation (PEAC) on MDRO patient management. Methods: We conducted a prospective historical controlled study based on PEAC in MDRO patients. The retrospective control group was patients hospitalized 18 months before the PEAC initiation, and the prospective PEAC group was patients hospitalized 18 months after the PEAC initiation. Primary endpoint was 30-day all-cause mortality. Secondary outcomes were MDRO clinical outcome, duration of antibiotic use, length of stay, antibiotic consumption and antibiotic costs. Further subgroup analysis of secondary outcomes was performed by the condition at admission, MDRO pathogenicity and MDRO clinical outcome. Results: 188 MDRO patients were included. After adjusting for potential predictors, PEAC reduced the 30-day all-cause mortality by 70% (HR 0.30, 95% CI 0.09–0.96, p = 0.042). PEAC group had clinical improvement than control group (89.47% vs. 65.59%, p < 0.001), especially in patients with non-severe clinical conditions at admission (98.41% vs. 70.18%, p < 0.001). However, no significant differences were found between groups in length of stay, antibiotics consumption, and antibiotics costs. Conclusion: Early active pharmacy ID consultation can reduce 30-day all-cause mortality and improve clinical outcomes in MDRO patients. |
format | Online Article Text |
id | pubmed-10017476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100174762023-03-17 The impact of pharmacist early active consultation (PEAC) on multidrug resistance organism treatment outcomes: A prospective historically controlled study Du, Qian Xi, Xin Dong, Jie Zhang, Tongyan Li, Dongxuan Dong, Yuzhu Li, Wenjun Huang, Guili Zhu, Jun Ran, Hailong Gou, Jinghui Chen, Cheng Bai, Zhanfeng Liu, Qinglong Yao, Wei Zhang, Lei Bi, Yutian Liu, Songqing Front Pharmacol Pharmacology Background and aim: Infectious disease (ID) consultation can improve multidrug-resistant organism (MDRO) treatment outcomes. However, the impact of clinical pharmacists’ ID consultation on MDRO therapy, especially early initiation, has not been reported. In this study, we try to explore the impact of the pharmacist early active consultation (PEAC) on MDRO patient management. Methods: We conducted a prospective historical controlled study based on PEAC in MDRO patients. The retrospective control group was patients hospitalized 18 months before the PEAC initiation, and the prospective PEAC group was patients hospitalized 18 months after the PEAC initiation. Primary endpoint was 30-day all-cause mortality. Secondary outcomes were MDRO clinical outcome, duration of antibiotic use, length of stay, antibiotic consumption and antibiotic costs. Further subgroup analysis of secondary outcomes was performed by the condition at admission, MDRO pathogenicity and MDRO clinical outcome. Results: 188 MDRO patients were included. After adjusting for potential predictors, PEAC reduced the 30-day all-cause mortality by 70% (HR 0.30, 95% CI 0.09–0.96, p = 0.042). PEAC group had clinical improvement than control group (89.47% vs. 65.59%, p < 0.001), especially in patients with non-severe clinical conditions at admission (98.41% vs. 70.18%, p < 0.001). However, no significant differences were found between groups in length of stay, antibiotics consumption, and antibiotics costs. Conclusion: Early active pharmacy ID consultation can reduce 30-day all-cause mortality and improve clinical outcomes in MDRO patients. Frontiers Media S.A. 2023-03-02 /pmc/articles/PMC10017476/ /pubmed/36937879 http://dx.doi.org/10.3389/fphar.2023.1128219 Text en Copyright © 2023 Du, Xi, Dong, Zhang, Li, Dong, Li, Huang, Zhu, Ran, Gou, Chen, Bai, Liu, Yao, Zhang, Bi and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Du, Qian Xi, Xin Dong, Jie Zhang, Tongyan Li, Dongxuan Dong, Yuzhu Li, Wenjun Huang, Guili Zhu, Jun Ran, Hailong Gou, Jinghui Chen, Cheng Bai, Zhanfeng Liu, Qinglong Yao, Wei Zhang, Lei Bi, Yutian Liu, Songqing The impact of pharmacist early active consultation (PEAC) on multidrug resistance organism treatment outcomes: A prospective historically controlled study |
title | The impact of pharmacist early active consultation (PEAC) on multidrug resistance organism treatment outcomes: A prospective historically controlled study |
title_full | The impact of pharmacist early active consultation (PEAC) on multidrug resistance organism treatment outcomes: A prospective historically controlled study |
title_fullStr | The impact of pharmacist early active consultation (PEAC) on multidrug resistance organism treatment outcomes: A prospective historically controlled study |
title_full_unstemmed | The impact of pharmacist early active consultation (PEAC) on multidrug resistance organism treatment outcomes: A prospective historically controlled study |
title_short | The impact of pharmacist early active consultation (PEAC) on multidrug resistance organism treatment outcomes: A prospective historically controlled study |
title_sort | impact of pharmacist early active consultation (peac) on multidrug resistance organism treatment outcomes: a prospective historically controlled study |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017476/ https://www.ncbi.nlm.nih.gov/pubmed/36937879 http://dx.doi.org/10.3389/fphar.2023.1128219 |
work_keys_str_mv | AT duqian theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT xixin theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT dongjie theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT zhangtongyan theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT lidongxuan theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT dongyuzhu theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT liwenjun theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT huangguili theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT zhujun theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT ranhailong theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT goujinghui theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT chencheng theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT baizhanfeng theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT liuqinglong theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT yaowei theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT zhanglei theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT biyutian theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT liusongqing theimpactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT duqian impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT xixin impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT dongjie impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT zhangtongyan impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT lidongxuan impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT dongyuzhu impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT liwenjun impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT huangguili impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT zhujun impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT ranhailong impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT goujinghui impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT chencheng impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT baizhanfeng impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT liuqinglong impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT yaowei impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT zhanglei impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT biyutian impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy AT liusongqing impactofpharmacistearlyactiveconsultationpeaconmultidrugresistanceorganismtreatmentoutcomesaprospectivehistoricallycontrolledstudy |